A phase I study evaluating the safety and efficacy of SGI-110 followed by combined durvalumab (MEDI4736) plus tremelimumab in subjects with extensive-stage small cell lung cancer (ES-SCLC)
A study for patients with small cell lung cancer using study drug SGI-110
Sponsor: Medimmune
Enrolling: Male and Female Patients
IRB Number: AAAQ8257
U.S. Govt. ID: NCT03085849
Contact: Catherine Shu, MD: 212-305-3997 / cas2145@columbia.edu
Additional Study Information: This study will investigate the safety and effectiveness of the study drug SGI-110 in combination with two immunotherapy drugs named durvalumab and tremelimumab in patients with small cell lung cancer who have progressed on other treatments. SGI-110 is a form of chemotherapy known as a "hypomethylating agent" and may help the immunotherapy work better.
This study is closed
Investigator
Catherine Shu, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have a confirmed diagnosis of small cell lung cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Catherine Shu, MD
cas2145@columbia.edu
212-305-3997
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE